Patient Adherence to Osteoporosis Medications
- 188 Downloads
Adherence to osteoporosis medications is relatively poor. Approximately 20–30% of patients taking daily or weekly treatments may suspend their treatment within 6 to 12 months of initiating therapy. Patients with poor adherence increase their risk of osteoporotic fractures and hospitalisation. The majority of patients who discontinue therapy appear to do so because of drug-induced adverse effects. Fear of adverse effects or other health risks is another commonly cited reason for discontinuing therapy. Factors associated with medication adherence include fractures, regular exercise, female sex, fewer non-osteoporosis medications and co-morbidities, early menopause, willingness to take medications, awareness of osteoporosis status based on a diagnostic test, anti-inflammatory therapy and corticosteroid therapy. Factors associated with non-adherence include adverse effects, pain and being unsure about bone mineral density (BMD) test results. Bisphosphonates, a common class of drugs for treating osteoporosis, have specific administration requirements (e.g. fasting, remaining upright and not ingesting other medications concomitantly). Patient surveys indicate that 12–18% of patients report non-compliance with at least one administration rule. Strategies to increase adherence include reducing administration frequency to weekly or monthly, monitoring patients with bone markers and BMD testing, providing adequate instructions, practitioner feedback and support, and educational materials and sessions. Future studies are needed regarding strategies to increase adherence to osteoporosis medications.
KeywordsBone Mineral Density Osteoporosis Hormone Replacement Therapy Raloxifene Strontium Ranelate
JD Adachi has acted as a consultant for and/or received honoraria from Amgen, Astra Zeneca, sanofi-aventis, Eli Lilly, GlaxoSmithKline, Merck, Novartis, NPS Allelix, Pfizer, Procter & Gamble, Roche, Servier, Wyeth.
Alexandra Papaioannou has acted as a consultant and received honoraria or grants from Eli Lilly, Merck Frosst Canada, Procter & Gamble Pharmaceuticals Canada and sanofi-aventis, and has acted as a consultant and received honoraria from Novartis.
Courtney Kennedy, Lisa Dolovich and Elaine Lau have no potential conflicts of interest of direct relevance to the content of this review.
No sources of funding were used to assist in the preparation of this review.
- 1.Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90(1): 107–110Google Scholar
- 13.National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002Google Scholar
- 17.Sackett DL. Introduction. In: Sackett DL, editor. Compliance with therapeutic regimens. Baltimore MD): Johns Hopkins University Press, 1976Google Scholar
- 18.Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4: CD000011Google Scholar
- 28.Goettsch WG, Penning F, Erkens JE, et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S278Google Scholar
- 29.Weycker D, Macarios D, Oster G. Adherence with drug therapy and risk of fracture among women with postmenopausal osteoporosis [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S383Google Scholar
- 31.Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study [abstract]. Calcif Tissue Int 2003, 72Google Scholar
- 37.Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282(7): 637–45PubMedCrossRefGoogle Scholar
- 48.Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4(5): 488–92Google Scholar
- 49.Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26(2): 245–56PubMedCrossRefGoogle Scholar
- 53.Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): Sl–34Google Scholar
- 54.Eli Lilly and Company. About taking EVISTA [online]. Available from URL: http://www.evista.com [Accessed 2006 Mar 16]
- 56.Lombas C, Hakim C, Zanchetta J. Compliance with alendronate treatment in an osteoporosis clinic [abstract]. J Bone Miner Res 2001; 15: S529Google Scholar
- 68.Roche. FDA approves once-monthly Boniva for osteoporosis [online]. Available from URL: http://www.roche.com/medcor-2005-03-29 [Accessed 2006 Oct 23]
- 72.Emkey R. BNSLRC. BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S416Google Scholar
- 82.Royal Pharmaceutical Society of Great Britain. From compliance to concordance: towards shared goals in medicine taking. London: Royal Pharmaceutical Society of Great Britain, 1997Google Scholar